Results 141 to 150 of about 59,797 (283)

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms. [PDF]

Front Endocrinol (Lausanne), 2021
Pivonello C, Patalano R, Negri M, Pirchio R, Colao A, Pivonello R, Auriemma RS.   +6 more
europepmc   +1 more source

Dopamine Agonists Used as Monotherapy in De Novo PD Patients: Comparisons With Selegiline

, 1992
Studies indicate that selegiline, a monoamine oxidase type B inhibitor, slows progression of Parkinson\u27s disease (PD) and delays th need for levodopa.
Lieberman, Abraham N.
core  

Indirect Striatal Projection Neurons Drive a D2 Receptor‐Dependent Pathway to Dyskinesia and Dystonia

Movement Disorders, EarlyView.
D2 receptor ablation in indirect‐pathway striatal neurons reduces or abolishes dyskinetic and dystonic behaviors induced by L‐DOPA or D2 receptor agonists, respectively. Contralateral turning is reduced, while forward locomotion is increased. These effects are associated with modulation of neuronal activity in dorsal striatum and external globus ...
Laura Andreoli, Teodor Nyman, Elena Espa, Johan Jakobsson, Osama F. Elabi, Maria Angela Cenci   +5 more
wiley   +1 more source

Dopamine agonists for preventing ovarian hyperstimulation syndrome. [PDF]

Cochrane Database Syst Rev, 2021
Tang H, Mourad SM, Wang A, Zhai SD, Hart RJ.   +4 more
europepmc   +1 more source

Metabolic and Volumetric Alterations in the Basal Ganglia and the Cerebellum in Dopa‐Responsive Dystonia in Symptomatic and Asymptomatic GCH1 Mutation Carriers

Movement Disorders, EarlyView.
ABSTRACT Background Dopa‐responsive dystonia is caused by pathogenic variants in the GCH1 gene. Although its clinical features and reduced penetrance are known, in vivo metabolic and structural alterations in symptomatic (sMC) and asymptomatic mutation carriers (aMC) remain poorly understood.
Jannik Prasuhn, Leon van Well, Marta M. Pokotylo, Feline Hamami, Joke‐Lina Aßmann, Katja Lohmann, Maximilian G. Ködderitzsch‐Mertins, Julia Henkel, Jan Uter, Alexander Münchau, Christine Klein, Anne Weissbach, Norbert Brüggemann   +12 more
wiley   +1 more source

Dopamine Agonists in the Management of Non-Functioning Pituitary Adenomas. [PDF]

Acta Endocrinol (Buchar), 2021
Capatina C, Poiana C.
europepmc   +1 more source

Expanding the Phenotype of PARK‐PRKN to Spastic Paraplegia: A Report of Two Cases

Movement Disorders Clinical Practice, EarlyView.
Nicolas Geoffre, Thomas Ollivier, Guillaume Baille, Luc Defebvre, Vincent Huin, Eugenie Mutez   +5 more
wiley   +1 more source

Revisiting the Association Between Calcium Channel Blockers and Parkinson's Disease in the E3N Cohort

Movement Disorders, EarlyView.
Abstract Background Previous studies on calcium channel blockers (CCBs) and Parkinson's disease (PD) risk reached conflicting conclusions. Objectives We examined the relationship between CCBs and PD in the E3N cohort of French women followed for 15 years (2004–2018), while taking into account the potential for reverse causation.
Emilie Moutard, Agnès Fournier, Émeline Courtois, Fanny Artaud, Pascale Tubert‐Bitter, Emmanuel Roze, Ismaïl Ahmed, Anne C.M. Thiébaut, Alexis Elbaz, Thi Thu Ha Nguyen   +9 more
wiley   +1 more source

Othello Syndrome Induced by Dopamine Agonists in Parkinson's Disease: A Case Report. [PDF]

Case Rep Psychiatry
Ahmed GU, Ahmed HU, Raza AA, Samadi A.
europepmc   +1 more source

Quantitative Evaluation of Pupil Responses in Patients with Prolactinomas Being Treated with Dopamine Agonists. [PDF]

Neuroophthalmology, 2022
Ava S, Hazar L, Karahan M, Erdem S, Dursun ME, Pekkolay Z, Keklikçi U.   +6 more
europepmc   +1 more source